

RESULT 28
 AAN61206
 ID AAN61206 standard; DNA; 15 BP.
 XX AC AAN61206;
 XX DT 03-OCT-2002 (revised)
 XX DT 22-AUG-1991 (first entry)
 XX DE Sequence of probe 2 complementary to 3' tissue plasminogen activator (t-
 XX DE PA) position 634-648.
 XX KW Fibrinolytic activity; thrombolytic disease; therapy.
 XX OS Homo sapiens.
 XX PN EP174835-A.
 XX PD 19-MAR-1986.
 XX PF 10-SEP-1985; 85EP-00306432.
 XX PR 11-SEP-1984; 84US-00648663.
 XX PR 19-OCT-1984; 84US-00663025.
 XX PA (UPJO) UPJOHN CO.
 XX PI Gill GS;
 XX DR WPI; 1986-077218/12.
 XX PT New tissue plasminogen activator expressed by yeast - useful as
 XX PT fibrinolytic agent with high activity for treating thrombolytic diseases.
 XX PS Example; Page 27; 61pp; English.
 XX CC AAN61205, AAN61206 and AAN61207 are used either as probes or primers for
 XX CC t-PA cDNA synthesis. T-PA and its analogues have fibrinolytic activity,
 XX CC and have the high activity of known tissue plasminogen activator.
 XX CC (Updated on 03-OCT-2002 to add missing OS field.)
 XX SQ Sequence 15 BP; 1 A; 2 C; 7 G; 5 T; 0 U; 0 Other;
 Query Match 3.7%; Score 12.4; DB 1; Length 15;
 Score over Length 82.7%;
 Best Local Similarity 92.9%; Pred. No. 5.5e+06;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 260 GGGGTTTGAGTCAC 273
 Db 1 GGGGTTTGAGTCCTC 14

RESULT 29
 AAO24118
 ID AAO24118 standard; DNA; 15 BP.
 XX AC AAO24118;
 XX DT 04-NOV-1992 (first entry)
 XX DE Probe/primer #2 for tPA cDNA.
 XX KW tissue plasminogen activator analogue; active site; tPA finger; domain;
 XX KW tPA kringle 2 domain; thrombi; thrombotic disease; increased half life;
 XX KW increased fibrin affinity; ss.
 XX OS Synthetic.
 XX PN USS106741-A.
 XX DT 21-APR-1992.

XX 12-JUN-1991; 91US-00714365.
 XX 20-DEC-1985; 85US-00811607.
 XX 19-SEP-1986; 86US-00909482.
 XX 28-JAN-1987; 87US-00023491.
 XX (UPJO) UPJOHN CO.
 XX Marotti KR, Rehberg EF; Theriault NY;
 XX WPI; 1992-159371/19.
 XX PT New tissue plasminogen activator analogues - having active site, finger
 XX PT domain and native kringle 2 domain, obtd. using recombinant DNA
 XX PT techniques.
 XX PS Disclosure; Col 18; 36pp; English.
 XX CC This oligonucleotide is used as a primer for the synthesis of tPA cDNA, It
 XX CC using enriched polyA selected mRNA obtained from Bowes Melanoma cells. It
 XX CC is complementary to 3' tPA nucleotides 634-648. The cDNA is then cloned
 XX CC into pBR322 and transformed into E. coli. Colonies are then screened in
 XX CC situ using this probe, and those hybridising positive are selected for
 XX CC secondary screening using PstI restriction analysis to determine if the
 XX CC digestion products are consistent with the PstI restriction map. This
 XX CC sequence is also used as a primer to generate a cDNA library to complete
 XX CC the 5' end of tPA (for isolation of start of 5' end see AAQ24117). 3
 XX CC portions of cDNA encoding the tPA are finally isolated and these ligated
 XX CC together with pKC7 to give a plasmid containing the complete cDNA
 XX CC sequence for tPA. See also AAQ24117-9, 21, AAR22664
 XX SQ Sequence 15 BP; 1 A; 2 C; 7 G; 5 T; 0 U; 0 Other;
 Query Match 3.7%; Score 12.4; DB 2; Length 15;
 Score over Length 82.7%;
 Best Local Similarity 92.9%; Pred. No. 5.5e+06;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 260 GGGGTTTGAGTCAC 273
 Db 1 GGGGTTTGAGTCCTC 14

RESULT 30
 AAT55764
 ID AAT55764 standard; RNA; 15 BP.
 XX AC AAT55764;
 XX DT 25-MAR-2003 (revised)
 XX DT 25-MAR-1997 (first entry)
 XX DE Human TNF-alpha hammerhead ribozyme target sequence (nt position 1187).
 XX KW Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
 XX KW gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
 XX KW intercellular adhesion molecule; rel A; tumour necrosis factor;
 XX KW TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
 XX KW translocation; chronic myelogenous leukaemia; CML; cancer;
 XX KW Philadelphia chromosome; inflammation; autoimmune disease;
 XX KW atherosclerosis; myocardial infarction; stroke; restenosis;
 XX KW transplant rejection; rheumatoid arthritis; psoriasis;
 XX KW myocardial ischaemia; Kawasaki disease; septic shock; HIV;
 XX KW human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
 XX KW ss.
 XX OS Homo sapiens.
 XX PN WO9523225-A2.
 XX PD 31-AUG-1995.

<!--StartFragment-->RESULT 66

US-08-292-620A-23

; Sequence 23, Application US/08292620A

; Patent No. 5837542

; GENERAL INFORMATION:

; APPLICANT: Susan Grimm

; APPLICANT: Dan T. Stinchcomb

; APPLICANT: James McSwiggen

; APPLICANT: Sean Sullivan

; APPLICANT: Kenneth G. Draper

; TITLE OF INVENTION: RIBOZYME TREATMENT OF

; TITLE OF INVENTION: DISEASES OR CONDITIONS

; TITLE OF INVENTION: RELATED TO LEVELS OF

; TITLE OF INVENTION: INTRACELLULAR ADHESION

; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)

; NUMBER OF SEQUENCES: 2390

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon

; STREET: 633 West Fifth Street

; STREET: Suite 4700

; CITY: Los Angeles

; STATE: California

; COUNTRY: U.S.A.

; ZIP: 90071-2066

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; MEDIUM TYPE: storage

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: IBM P.C. DOS 5.0

; SOFTWARE: Word Perfect 5.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/292,620A

; FILING DATE: August 17, 1994

; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:

; PRIOR APPLICATION DATA: including application

; PRIOR APPLICATION DATA: described below:

two

; APPLICATION NUMBER: 08/008,895

; FILING DATE: January 19, 1993

; APPLICATION NUMBER: 07/989,849

; FILING DATE: December 7, 1992

; ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard J.

; REGISTRATION NUMBER: 32,327

; REFERENCE/DOCKET NUMBER: 208/149

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (213) 489-1600

; TELEFAX: (213) 955-0440

; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 23:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 15 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

US-08-292-620A-23

Query Match 4.0%; Score 13.4; DB 2; Length 15;

Score over Length 89.3%;

Best Local Similarity 66.7%; Pred. No. 4.8e+05;

Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 304 CAGACATCTGTGTAC 318

|||||:|:|:|

Db 1 CAGACAUCUGUGUCC 15

<!--EndFragment-->